Hørsholm, Denmark, October 4, 2004 – LifeCycle Pharma A/S announced today that it has initiated clinical trials on an improved tablet formulation of fenofibrate.
We expect to file for market authorization of our superior fenofibrate product in 2005, providing LifeCycle Pharma with its first launch,” said Jan Møller Mikkelsen, President and CEO of LifeCycle Pharma. “LifeCycle Pharma has several products in clinical trials, but fenofibrate is the first that we advance into clinical trials independently of a partner.” “In less than 12 months, we have developed a superior fenofibrate tablet formulation, from idea to clinical trials,” added Michael Wolff Jensen, Executive Vice President & CFO. “This demonstrates the remarkable efficiency and power of LifeCycle Pharma´s proprietary MeltDose® technology.
About Fenofibrate
Sales of Fenofibrate were in excess of $800 million in 2003, and continue to demonstrate strong growth. In the United States, sales of Tricor® (fenofibrate) have increased by 40 percent over the past 12 months. Tricor® is currently marketed by Abbott in the United States, and Fournier in Europe. It is a member of the fibrate class of cholesterol-lowering drugs, and remains a cornerstone for managing lipid levels in patients with dislipidemia.
About LifeCycle Pharma A/S
LifeCycle Pharma is a biotechnology company with a clinical pipeline of value-added formulations of already approved products. LifeCycle Pharma has developed the most efficacious, clinically validated, drug-delivery platform for solving the insufficiencies of drugs with low water solubility, thus improving the bioavailability of marketed drugs and New Chemical Entities (NCEs). The resulting novel formulations created by LifeCycle Pharma can better target and remain within the therapeutic index, thus leading to drugs with vastly improved efficacy and safety profiles. LifeCycle Pharma is collaborating with Recordati S.p.A. on a modified-release tablet formulation of Lercanidipine. Lercanidipine is an oral calcium-channel blocker for hypertension, and is marketed by Recordati under the brand name of Zanidip®. LifeCycle Pharma also collaborates with H. Lundbeck A/S on several product opportunities in the area of CNS. For more information about LifeCycle Pharma A/S, please visit www.lcpharma.com
